Medicines for Malaria Venture (MMV) recently announced that the Australian Therapeutic Goods Administration (TGA) had approved the use of single-dose Kozenis (tafenoquine) in children in combination with chloroquine for the prevention of relapse of Plasmodium vivax (P. vivax) malaria.
The TGA approval confirmed on March 14, 2022, includes a novel, 50 mg dispersible tablet that can be dispersed in water and developed by GSK in partnership with MMV to facilitate use in children who are disproportionately affected by the disease.
Read More